OncoMatch/Clinical Trials/NCT06321484
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Official title: A Phase 1b Study of Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cell Therapy in Recurrent Ovarian Cancer
Is NCT06321484 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies multiple treatments including Cytokine-Induced Memory-like Natural Killer Cells and Interleukin 2 for platinum-resistant ovarian cancer.
Treatment: Cytokine-Induced Memory-like Natural Killer Cells · Interleukin 2 — The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer (HGOC). Names of the study therapies involved in this study are: CIML NK (cellular therapy) Interleukin-2 (IL-2)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Allowed: BRCA1 mutation
Allowed: BRCA2 mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic therapy
Must have received: parp inhibitor
Lab requirements
Blood counts
absolute neutrophil count ≥1,000/mcl; platelets ≥75,000/mcl
Kidney function
serum creatinine ≤2.0 mg/dl or gfr ≥40 ml/min/1.73 m2
Liver function
Exact limits: see the full eligibility criteria on this page.
Cardiac function
Exact limits: see the full eligibility criteria on this page.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06321484 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy and parp inhibitor.
Is there an age limit?
Yes. Patients must be 85 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages